Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-23T17:55:07.714Z Has data issue: false hasContentIssue false
  • English
  • Français

Outcomes for Assessment of Symptomatic and Stabilization/Disease Modifying Drugs

Published online by Cambridge University Press:  02 December 2014

Serge Gauthier
Serge Gauthier*
Affiliation:
The Alzheimer Disease Research Unit, McGill Centre for Studies in Aging, Verdun, Quebec, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The safety and efficacy of current symptomatic drugs for AD was established using parallel groups taking different doses of active drugs vs placebo over three to twelve months, whereas drugs with potential stabilizing/disease modifying effects are being tested by adding new compounds or placebo to standard symptomatic drugs over 12 to 18 months. Delaying progression to disease milestones may offer additional validity to these studies. It is unclear if biological and neuroimaging markers will add to the clinical evidence.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 34 , Issue S1 , March 2007 , pp. S23 - S26
Copyright
Copyright © The Canadian Journal of Neurological 2007

References

1. Galasko, D, Edland, SD, Morris, JC, Clarck, C, Mohs, R, Koss, E. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part IX. Clinical milestones in patients with Alzheimer’s disease followed over 3 years. Neurology. 1995; 45: 1451–5.Google Scholar
2. Gauthier, S, Reisberg, B, Zaudig, M, Petersen, RC, Ritchie, K, Broich, K, et al. Mild cognitive impairment. Lancet. 2006; 367: 1262–70.Google Scholar
3. Sano, M, Ernesto, C, Thomas, RG, Klauber, MR, Schafer, K, Grundman, M, et al. A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med. 1997; 336: 1216–22.Google Scholar
4. Rosen, WG, Mohs, RC, Davis, KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984; 141: 1356–64.Google Scholar
5. Galasko, D, Bennett, D, Sano, M, Ernesto, C, Thomas, R, Grundman, M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. Alzheimer Dis Assoc Disord. 1997; 11 (Suppl 2): S33–9.CrossRefGoogle ScholarPubMed
6. Reisberg, B, Borenstein, J, Salob, SP, Ferris, SH, Franssen, E, Georgotas, A. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry. 1987; 48: (Suppl 5), S9–15.Google ScholarPubMed
7. Gélinas, I, Gauthier, L, McIntyre, M, Gauthier, S. Development of a functional measure for persons with Alzheimer’s disease: the Disability Assessment for Dementia. Am J Occup Ther. 1999; 53: 471–81.CrossRefGoogle ScholarPubMed
8. Cummings, JL, Mega, M, Gray, K, Rosenberg-Thompson, S, Caruso, DA, Gornbein, J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44: 2308–14.Google Scholar
9. Panisset, M, Roudier, M, Saxton, J, Boller, F. Severe Impairment Battery: a neuropsychological test for severely demented patients. Arch Neurol. 1994; 51, 41–5.Google Scholar
10. Fahn, S, Elton, R. United Parkinson’s Disease Rating Scale. In Fahn, S, Marsden, C, Golstein, M, et al, editors. Recent development in Parkinson’s disease. Florham Park: Macmillan Healthcare. 1987; 153–63.Google Scholar
11. Leber, P. Guidelines for clinical evaluation of antidementia drugs. Washington, DC: US Food and Drug Administration, 1990.Google Scholar
12. Folstein, MF, Folstein, SE, McHugh, PR. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res. 1975; 12: 189–98.CrossRefGoogle Scholar
13. Winblad, B, Engedal, K, Soininen, H, Verhey, F, Waldemar, G, Wimo, A, et al. Donepezil Nordic Study Group: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001; 57: 489–95.Google Scholar
14. Schneider, LS. Cholinesterase inhibitors for vascular dementia? Lancet Neurology. 2003; 2: 658–9.Google Scholar
15. Cohen-Mansfield, J, Marx, MS, Rosenthal, AS. A description of agitation in a nursing home. J Gerontology. 1989; 44: M77–M84.Google Scholar
16. Gauthier, S, Feldman, H, Hecker, J, Vellas, B, Ames, D, Subbiah, P, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatrics. 2002; 14: 389–404.Google Scholar
17. Gauthier, S, Wirth, Y, Möbius, HJ. Effects of memantine on behavioral symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomized, controlled studies. Int J Geriatr Psychiatry. 2005; 20: 459–64.CrossRefGoogle Scholar
18. Doody, RS, Winblad, B, Jelic, V. Memantine: a glutamate antagonist for treatment of Alzheimer’s disease. In Gauthier, S, Scheltens, P, Cummings, JL, editors. Alzheimer’s Disease and Related Disorders Annual 2004, London: Martin Dunitz. 137–44.Google Scholar
19. Hughes, CP, Berg, L, Danziger, WL, Coben, LA, Martin, RL. A new clinical scale for the staging of dementia. Brit J Psychiatry. 1982; 140: 566–72.Google Scholar